Galectin Therapeutics (GALT) Accumulated Expenses (2010 - 2026)

Galectin Therapeutics' Accumulated Expenses history runs 17 years deep, the most recent figure standing at $4.2 million for Q1 2026.

• On a quarterly basis, Accumulated Expenses fell 39.29% year-over-year to $4.2 million in Q1 2026; TTM through Mar 2026 was $4.2 million, a 39.29% decrease from a year earlier, with the FY2025 full-year figure at $4.7 million, up 210.05% from the prior year.
• Accumulated Expenses declined to $4.2 million in Q1 2026 per GALT's latest filing, from $4.7 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $10.9 million in Q2 2024 and bottomed at $386000.0 in Q1 2023.
• The 5-year median for Accumulated Expenses is $4.2 million (2026), against an average of $4.2 million.
• Across the five-year window, Accumulated Expenses sank 94.94% in 2023 and soared 2189.12% in 2024, its largest moves.
• Year by year, Accumulated Expenses stood at $973000.0 in 2022, then grew by 16.03% to $1.1 million in 2023, then soared by 34.9% to $1.5 million in 2024, then soared by 210.05% to $4.7 million in 2025, then declined by 11.35% to $4.2 million in 2026.
• Per Business Quant, the three latest GALT Accumulated Expenses figures stand at $4.2 million (Q1 2026), $4.7 million (Q4 2025), and $1.1 million (Q3 2025).